Quarterly on ScheduleHello all,
After reading the latest NR I am left feeling a bit disappointed. While the release highlights the accomplishments ( and there are many), it did not provide any detail on the recent Arc deal. Good that they will seek approval for additional sites for TIGRIS. Further, there seems to be some foreshadowing to another raise from the
company
"While the Company continues to maintain a low cost operating structure for its base business operations, it anticipates its operating costs to increase throughout 2022 as Spectral’s Tigris trial enrolment is expected to increase, combined with incremental costs associated with Dialco’s upcoming usability trial for DIMI and the increase in field resources for the marketing and commercialization activities of its RRT devices."
Hopefully it won't come to more dilution. My conviction in this company is still strong. Just wanted a little bit more.
PM